1. Home
  2. GERN vs OCSL Comparison

GERN vs OCSL Comparison

Compare GERN & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.36

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$12.64

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
OCSL
Founded
1990
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
1996
2007

Fundamental Metrics

Financial Performance
Metric
GERN
OCSL
Price
$1.36
$12.64
Analyst Decision
Hold
Hold
Analyst Count
3
4
Target Price
$2.17
$12.63
AVG Volume (30 Days)
9.0M
472.0K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
12.73%
EPS Growth
51.85
N/A
EPS
N/A
0.20
Revenue
$1,065,000.00
N/A
Revenue This Year
$26.91
N/A
Revenue Next Year
$43.75
$0.31
P/E Ratio
N/A
$63.30
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$10.63
52 Week High
$2.01
$14.31

Technical Indicators

Market Signals
Indicator
GERN
OCSL
Relative Strength Index (RSI) 40.83 43.08
Support Level $1.24 $12.31
Resistance Level $1.46 $12.72
Average True Range (ATR) 0.08 0.21
MACD -0.02 -0.09
Stochastic Oscillator 3.85 7.19

Price Performance

Historical Comparison
GERN
OCSL

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

Share on Social Networks: